In mice bearing DFCI081 xenografts (harboring EGFR Del19 and METamp), tepotinib, alone or combined with EGFR-TKIs (rociletinib, erlotinib, or afatinib), induced complete tumor regression (60). Here, EGFR is linked to neoplasm.